Form 4: Outlook Therapeutics Director Buys Shares
Insider Transaction (Form 4)
Faisal Ghiath Sukhtian, a Director of Outlook Therapeutics, Inc., purchased 95,398 shares of common stock on July 29, 2026 for $1.05 per share.
Summary
- Open-market purchase: acquired 95,398 Common Stock at $1.05 ($99,996) on July 29, 2026; holds 220,972 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $99,996, committing personal capital to the stock.
Insider Transactions
Faisal Ghiath Sukhtian — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-29 | Open-market purchase | Common Stock | 95,398 | $1 | $100.0K | 220,972 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-29 | Open-market purchase (95,398 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., bullish, Faisal Ghiath Sukhtian
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.